If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works.
read more
Source: NY Times
23:57, June 5, 2021
Pam Belluck and Rebecca Robbins